Viracta Therapeutics (VIRX) Financials
Newest figures come from the filing for Q3 FY2024, filed Nov 13, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VIRX SEC filings page.
This page shows Viracta Therapeutics Inc (VIRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Viracta's reported numbers describe a research-led business where rising development spending consumes cash as the balance sheet shifts toward short-term obligations.
From FY2022 to FY2023, the net loss stayed near$49.2M and$51.1M , while operating cash outflow worsened from$35.5M to$39.9M . That cash pressure coincided with R&D rising 27.1% as SG&A fell28.8% , pointing to research intensity rather than broad overhead growth as the main spending pattern.
The balance sheet moved against the research effort: total assets fell 40.9% from FY2022 while total liabilities rose
Capital spending remained minor beside cash use: FY2023 capex was
Financial Health Signals
Viracta Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Viracta Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
Viracta Therapeutics Inc reported a net loss of $51.1M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Viracta Therapeutics Inc reported an operating loss of $50.7M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Viracta Therapeutics Inc's EBITDA was -$10.1M in Q3 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Viracta Therapeutics Inc reported a net loss of $10.6M in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Viracta Therapeutics Inc earned -$0.27 per diluted share (EPS) in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2024.
Cash & Balance Sheet
Viracta Therapeutics Inc recorded an outflow of $7.1M in free cash flow in Q3 2024, representing a cash shortfall after capex.
Viracta Therapeutics Inc held $13.1M in cash against $16.9M in long-term debt as of Q3 2024.
Not reported for Q3 2024.
Margins & Returns
None of these metrics is reported for Q3 2024.
Capital Allocation
Viracta Therapeutics Inc invested $7.2M in research and development in Q3 2024. This represents a decrease of 12.0% from the same quarter a year earlier. Against the prior quarter it is up 9.7%.
Not reported for Q3 2024.
VIRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $7.2M-12.0% | $6.5M-20.1% | $10.0M+30.9% | $9.4M+40.3% | $8.2M+14.3% | $8.2M+29.6% | $7.6M+24.8% | $6.7M-8.2% |
| SG&A Expenses | $3.0M-30.4% | $3.0M-28.5% | $3.9M-14.8% | $4.2M-14.7% | $4.3M-60.5% | $4.3M+1.7% | $4.6M+6.1% | $4.9M+21.3% |
| Operating Income | -$10.2Mn/m | -$9.6Mn/m | -$13.9Mn/m | -$13.6Mn/m | -$12.5Mn/m | -$12.4Mn/m | -$12.2Mn/m | -$11.6Mn/m |
| EBITDA | -$10.1Mn/m | -$9.5Mn/m | -$13.8Mn/m | N/A | -$12.3Mn/m | -$12.3Mn/m | -$12.1Mn/m | N/A |
| Interest Expense | $679K-28.8% | $697K-24.3% | $858K-2.5% | N/A | $953K+585.6% | $921K+625.2% | $880K+609.7% | N/A |
| Net Income | -$10.6Mn/m | -$9.8Mn/m | -$9.1Mn/m | -$13.8Mn/m | -$12.6Mn/m | -$12.5Mn/m | -$12.2Mn/m | -$10.3Mn/m |
| EPS (Basic) | -$0.27n/m | -$0.25n/m | -$0.23n/m | -$0.35n/m | -$0.33n/m | -$0.32n/m | -$0.32n/m | -$0.27 |
| EPS (Diluted) | -$0.27n/m | -$0.25n/m | -$0.23n/m | -$0.35n/m | -$0.33n/m | -$0.32-214.3% | -$0.32n/m | -$0.27 |
| Diluted Shares (Avg) | 40M+2.3% | 39M+2.2% | 39M+2.2% | N/A | 39M+2.6% | 39M+2.6% | 38M+2.5% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
VIRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.0M-66.9% | $31.3M-59.2% | $41.3M-51.8% | $56.7M-40.9% | $66.4M-19.2% | $76.9M-13.8% | $85.8M-12.8% | $96.0M-11.6% |
| Current Assets | $21.8M-66.2% | $31.1M-58.3% | $41.0M-50.9% | $55.0M-41.4% | $64.4M-19.1% | $74.6M-13.7% | $83.4M-12.5% | $93.7M-10.9% |
| Cash & Equivalents | $13.1M+2.1% | $14.0M-2.2% | $12.1M-33.4% | $12.3M-66.5% | $12.9M-45.2% | $14.3M-82.5% | $18.1M-80.4% | $36.8M-64.5% |
| Short-Term Investments | $8.0M-84.0% | $16.0M-72.6% | $27.5M-55.8% | $41.4M-23.8% | $50.1M-6.5% | $58.6M+3649.9% | $62.2Mn/m | $54.3Mn/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $28.6M-21.6% | $28.7M-20.6% | $30.3M-12.7% | $38.4M+10.0% | $36.4M+153.2% | $36.1M+196.9% | $34.7M+171.2% | $34.9M+146.0% |
| Current Liabilities | $28.6M-21.6% | $28.7M+88.3% | $30.3M+159.6% | $38.4M+283.3% | $36.4M+288.1% | $15.2M+110.7% | $11.7M+50.1% | $10.0M+10.2% |
| Non-Current Liabilities | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $20.9M+323.1% | $23.0M+358.8% | $24.9M+388.1% |
| Long-Term Debt | $16.9Mn/m | $18.7M-9.8% | $18.7M-18.2% | $0-100.0% | $0-100.0% | $20.8M+327.8% | $22.8M+371.7% | $24.9M+416.2% |
| Total Equity | -$6.6M-122.1% | $2.7M-93.5% | $11.1M-78.3% | $18.3M-70.0% | $30.0M-55.7% | $40.8M-47.0% | $51.1M-40.3% | $61.1M-35.3% |
| Retained Earnings | -$295.5Mn/m | -$284.9Mn/m | -$275.1Mn/m | -$265.9Mn/m | -$252.2Mn/m | -$239.6Mn/m | -$227.1Mn/m | -$214.9Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
VIRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.1Mn/m | -$9.8Mn/m | -$7.8Mn/m | -$10.0Mn/m | -$10.5Mn/m | -$8.0Mn/m | -$11.3Mn/m | -$7.9Mn/m |
| Depreciation & Amortization | $110K-14.1% | $96K-19.3% | $110K-9.8% | $123K+115.8% | $128K+184.4% | $119K+120.4% | $122K+125.9% | $57K-3.4% |
| Stock-Based Compensation | $1.3M-29.6% | $1.4M-30.4% | $1.8M-13.0% | N/A | $1.8M-76.8% | $2.0M+1.1% | $2.1M+19.2% | N/A |
| Capital Expenditures | $0 | N/A | N/A | $0n/m | N/A | N/A | N/A | $0-100.0% |
| Free Cash Flow | -$7.1M | N/A | N/A | -$10.0Mn/m | N/A | N/A | N/A | -$7.9Mn/m |
| Investing Cash Flow | $8.2M-10.3% | $11.7M+194.0% | $14.2Mn/m | $9.3Mn/m | $9.1Mn/m | $4.0Mn/m | -$7.3Mn/m | -$203Kn/m |
| Financing Cash Flow | -$1.9Mn/m | $43K-78.9% | -$6.6M-41337.5% | $218K-99.0% | $0-100.0% | $204K+750.0% | $16K+100.0% | $21.4Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VIRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -368.0%-337.4pp | -82.5%-58.6pp | -75.1%-58.2pp | -42.0%-15.8pp | -30.6%-16.9pp | -23.9%-11.6pp | -16.9%-4.8pp |
| Return on Assets | -48.1%-29.1pp | -31.4%-15.1pp | -22.1%-7.9pp | -24.3%-13.5pp | -19.0%+2.6pp | -16.2%-4.4pp | -14.2%-3.5pp | -10.8%-0.2pp |
| Current Ratio | 0.76-1.0x | 1.08-3.8x | 1.35-5.8x | 1.43-7.9x | 1.77-6.7x | 4.90-7.1x | 7.16-5.1x | 9.36-2.2x |
| Debt-to-Equity | N/A | 7.02+6.5x | 1.69+1.2x | 0.00-0.4x | 0.00-0.1x | 0.51+0.4x | 0.45+0.4x | 0.41+0.4x |
| Liabilities-to-Equity | N/A | 10.73+9.8x | 2.73+2.1x | 2.09+1.5x | 1.21+1.0x | 0.88+0.7x | 0.68+0.5x | 0.57+0.4x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Viracta Therapeutics Inc VIRX | FY2023 | N/A | -$51.1M | N/A | N/A | — |
| Lyra Therapeutics Inc LYRA | FY2025 | $398K | -$28.9M | N/A | $337K | — |
| Altamira Therapeutics Ltd CYTOF | FY2024 | N/A | -$8.5M | N/A | $405K | — |
| CERo Terapeutics Holding Inc CERO | FY2025 | N/A | N/A | N/A | $180K | — |
Where Viracta Therapeutics Inc Ranks
Frequently Asked Questions
No, Viracta Therapeutics Inc (VIRX) reported a net loss of $51.1M in fiscal year 2023.
Viracta Therapeutics Inc (VIRX) had EBITDA of -$50.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2023, Viracta Therapeutics Inc (VIRX) had $12.3M in cash and equivalents against $0 in long-term debt.
Viracta Therapeutics Inc (VIRX) has a return on equity of -278.7% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
Viracta Therapeutics Inc (VIRX) recorded an outflow of $40.0M in free cash flow during fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Viracta Therapeutics Inc (VIRX) recorded an outflow of $39.9M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
Viracta Therapeutics Inc (VIRX) had $56.7M in total assets as of fiscal year 2023, including both current and long-term assets.
Viracta Therapeutics Inc (VIRX) invested $138K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
Viracta Therapeutics Inc (VIRX) invested $33.4M in research and development during fiscal year 2023.
Viracta Therapeutics Inc (VIRX) had a current ratio of 1.43 as of fiscal year 2023, which is considered adequate.
Viracta Therapeutics Inc (VIRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2023. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Viracta Therapeutics Inc (VIRX) had a liabilities-to-equity ratio of 2.09 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Viracta Therapeutics Inc (VIRX) had a return on assets of -90.1% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2023, Viracta Therapeutics Inc (VIRX) held $53.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.9M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Viracta Therapeutics Inc (VIRX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Viracta Therapeutics Inc (VIRX) reported a net loss of $51.1M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Viracta Therapeutics Inc (VIRX) reported an operating loss of $50.7M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.